Has Sami Brake received payments from drug or device companies?

Yes. Drug and device makers reported $250,680 in general payments to Sami Brake across 297 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Sami Brake did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Sami Brake come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Sami Brake

Medical Oncology · Grand Rapids, MINPI 1043416811

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $182,749 of the $250,680 with a category attached, or 72.9%. Incyte Corporation accounts for 99.1% of it on its own, with 3 other manufacturers making up the rest. 2025 is the largest year on record at $73,552, 3.5 times the $20,801 reported in 2019. Among medical oncology clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$250,680in general payments, 2019–2025

Across 297 payments — averaging $844.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Incyte Corporation$248K
E.r. Squibb & Sons, L.L.C.$2K
Pharmacyclics LLC, An Abbvie Company$105
Bristol Myers Squibb$31

$90,447in research payments, 2019–2025

Across 170 payments — averaging $532.04 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Incyte Corporation$90K

What the payments were for

Consulting fees$24,89510%
Speaking & faculty fees$182,74973%
Travel & lodging$36,88715%
Food & beverage$6,1492%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Incyte Corporation	291	$248,469
E.r. Squibb & Sons, L.L.C.	1	$2,076
Pharmacyclics LLC, An Abbvie Company	4	$105
Bristol Myers Squibb	1	$31

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

JAKAFI$174,158
NIKTIMVO$67,425

How this compares

$250,680 in reported general payments places this provider in the 95th percentile of 170 medical oncology providers in Michigan.

See all medical oncology providers in Michigan →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Magnesium Sulfate	13	$70

Paid to pharmacies, not to this prescriber.

Other medical oncology in Grand Rapids

Anas AljanadiGrand Rapids$62K
Manish ThakurGrand Rapids$17K
Zeyad SakoGrand Rapids$10K
Harry ErbaAnn Arbor$1.1M
Philip PhilipDetroit$494K
Shirish GadgeelDetroit$413K
Patricia Lo RussoDetroit$322K
Ammar SukariDetroit$273K
Frank WeinbergAnn Arbor$195K
Wajahat KhanGrosse Pointe Woods$190K

See the full list for Michigan →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →